Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Medication

Glinides

31-01-2020 | Cardiovascular outcomes | News

Cardiovascular risks, benefits of different diabetes drugs quantified

An umbrella review of meta-analyses has demonstrated mixed associations between different glucose-lowering agents and cardiovascular outcomes in people with type 2 diabetes, with the results favoring sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists as cardioprotective agents.

21-06-2018 | Inpatient diabetes | Review | Article

Strategies to prevent readmission in high-risk patients with diabetes: The importance of an interdisciplinary approach

Gregory NS et al. Curr Diab Rep 2018; 18: 54. doi: 10.1007/s11892-018-1027-z

16-06-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

13-06-2018 | Neonatal diabetes | Review | Article

Congenital diabetes: Comprehensive genetic testing allows for improved diagnosis and treatment of diabetes and other associated features

Letourneau LR, Greeley SAW. Curr Diab Rep 2018; 18: 46. doi: 10.1007/s11892-018-1016-2

06-02-2018 | Post-transplant diabetes mellitus | Review | Article

Post-liver transplantation diabetes mellitus: A review of relevance and approach to treatment

Peláez-Jaramillo MJ et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0374-8

04-12-2017 | Cystic fibrosis | News

Repaglinide equals insulin for glucose control in cystic-fibrosis-related diabetes

The oral antidiabetic drug repaglinide controls blood glucose levels as effectively as insulin in patients with newly diagnosed cystic-fibrosis-related diabetes, study findings indicate.

31-07-2017 | Diabetes prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017; 1: 13–24. doi: 10.1007/s40256-017-0239-y

02-02-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Xu J, Rajaratnam R. Cardiovasc Diabetol 2017; 16: 18. doi: 10.1186/s12933-017-0499-5

Image Credits